Pharmacokinetic Analysis and In Vitro Synergy Evaluation of Cefiderocol, Sulbactam, and Tigecycline in an Extensively Drug-Resistant Acinetobacter baumannii Pneumonia Patient Receiving Continuous Venovenous Hemodiafiltration

Emir Kobic; Yasmeen Abouelhassan; Kumara Singaravelu; David P Nicolau

doi:10.1093/ofid/ofac484

Pharmacokinetic Analysis and In Vitro Synergy Evaluation of Cefiderocol, Sulbactam, and Tigecycline in an Extensively Drug-Resistant Acinetobacter baumannii Pneumonia Patient Receiving Continuous Venovenous Hemodiafiltration

Open Forum Infect Dis. 2022 Sep 21;9(10):ofac484. doi: 10.1093/ofid/ofac484. eCollection 2022 Oct.

Authors

Emir Kobic¹, Yasmeen Abouelhassan², Kumara Singaravelu³, David P Nicolau^{2

4}

Affiliations

¹ Department of Pharmacy, Banner University Medical Center, Phoenix, Arizona, USA.
² Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
³ Division of Infectious Diseases, Banner University Medical Center, Phoenix, Arizona, USA.
⁴ Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA.

Abstract

Antimicrobial treatments for extensively drug-resistant Acinetobacter baumannii (XDR-AB) infections have proven lackluster, while dosing challenges in patients receiving continuous renal replacement therapy continue. We describe a patient receiving cefiderocol, ampicillin/sulbactam, and tigecycline for XDR-AB while undergoing continuous venovenous hemodiafiltration. The clinical course, cefiderocol and sulbactam pharmacokinetics, and synergy assessments are described.

Keywords: Acinetobacter baumannii; cefiderocol; pharmacokinetics; synergy.

Publication types

Case Reports